Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 15/03/18 → 15/03/20 |
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic / Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Benserazide to L-dopa Responsive Parkinson's Disease Patients.
- O'Brien, Terence (Primary Chief Investigator (PCI))
- Bertram, Kelly (Chief Investigator (CI))
Project: Research